



# SEQUENCE LISTING

<110> MITCHELL, Lloyd G.  
OTTO, Edward  
MERRIL, Carl R.

<120> TRANS-SPLICING MEDIATED PHOTODYNAMIC THERAPY

<130> 027705.00026

<140> 10/658,617  
<141> 2003-09-09

<150> 10/374,784  
<151> 2003-02-25

<150> 60/359,948  
<151> 2002-02-25

<160> 21

<170> PatentIn version 3.3

<210> 1  
<211> 8  
<212> RNA  
<213> Artificial

<220>  
<223> 5' splice site consensus

<400> 1  
agguragu

<210> 2  
<211> 7  
<212> RNA  
<213> Artificial

<220>  
<223> branchpoint consensus sequence in mammals

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> n is a, c, g, or u

<400> 2  
ynyurac

<210> 3  
<211> 7  
<212> RNA  
<213> Artificial

<220>  
<223> yeast branchpoint consensus

<400> 3  
uacuaac 7

<210> 4  
<211> 7  
<212> RNA  
<213> Artificial

<220>  
<223> yeast consensus branchpoint

<400> 4  
uacuaac 7

<210> 5  
<211> 8  
<212> DNA  
<213> Artificial

<220>  
<223> GT rich sequences

<400> 5  
ygtgtt yy 8

<210> 6  
<211> 7  
<212> RNA  
<213> Artificial

<220>  
<223> branchpoint

<400> 6  
uacuaac 7

<210> 7  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> specific primer 5'

<400> 7  
aagcttttac tgctcg ttct tcagcacgc 29

<210> 8  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> Luc-33R

<400> 8

cagggtcgga ctcgatgaac

20

<210> 9  
<211> 21  
<212> DNA  
<213> Artificial

<220>  
<223> Luc-34F

<400> 9  
ggatatcgcc ctgatcaaga g

21

<210> 10  
<211> 6  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 3) functional PTM

<400> 10  
gctagc

6

<210> 11  
<211> 6  
<212> RNA  
<213> Artificial

<220>  
<223> (Fig. 3) Functional PTM

<400> 11  
ccgcgg

6

<210> 12  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 3) Functional PTM

<400> 12  
tactaactgg tacctcttct tttttttttg atatcctgca gggcggc

47

<210> 13  
<211> 6  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 7) binding domain

<400> 13  
gctagc

6

<210> 14  
<211> 6  
<212> RNA  
<213> Artificial

<220>  
<223> (Fig. 7) binding domain

<400> 14  
ccgcgg

6

<210> 15  
<211> 47  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 7) branchpoint

<400> 15  
tactaactgg tacctcttct tttttttttg atatcctgca gggcggc

47

<210> 16  
<211> 65  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 10) Target and PTM sequence

<400> 16  
ctcctggcct cgcgagatcc ctctcgtaa gggaggcaag cccgacgtcg tccagattgt

60

ccgca

65

<210> 17  
<211> 6  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 12) Luc-PTM13

<400> 17  
ctgcag

6

<210> 18  
<211> 71  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 15) Luc-PTM1

<400> 18

ccgcggaaca ttattataac gttgctcgaa tactaactgg tacctcttct tttttttttg 60  
atatacctgca g 71

<210> 19  
<211> 22  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 15) Luc-PTM TSD

<400> 19  
ctcgagcacc gatatacgtaa ct 22

<210> 20  
<211> 36  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 25B) Functional 3' ss

<400> 20  
tactaactct cttctttttt ttttgataac caggct 36

<210> 21  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> (Fig. 25B) Mutated 3' ss

<400> 21  
gaacaccta ctacatacat aacagttaac ccgct 35